Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review
Metastatic pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Until recently, cytotoxic chemotherapy was the only treatment option. Currently, there are subgroups of patients with PDAC either with somatic or germline mutations who are candidates for targeted agents. Germline mutations i...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-07-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/508533 |